Research progress on small-molecule inhibitors targeting TNIK in cancer treatment
10.16438/j.0513-4870.2023-1095
- VernacularTitle:TNIK小分子抑制剂在抗肿瘤治疗中的研究进展
- Author:
Meng-xiao CHEN
1
;
Yi HE
1
;
Shen-you NIE
2
Author Information
1. Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China
2. Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China; Department of Urology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
- Publication Type:Research Article
- Keywords:
Traf2- and Nck-interacting kinase;
nt/β-catenin;
small molecule inhibitor;
inase;
anti-tumor
- From:
Acta Pharmaceutica Sinica
2024;59(5):1151-1162
- CountryChina
- Language:Chinese
-
Abstract:
Traf2- and Nck-interacting kinase (TNIK) is closely related to the cancer occurrence, development, and prognosis. TNIK plays an important role in regulating Wnt/β-catenin pathway, thus becoming a potential target for cancer treatment. Various small-molecule TNIK inhibitors with diverse structures and potent in vitro activities have been developed to treat tumors. However, no TNIK inhibitor has entered clinical phase mainly due to poor selectivity, toxicity, and unsatisfied in vivo anti-tumor efficiency. This review summarizes the research progress of small molecule inhibitors targeting TNIK, with the aim of giving some guidance for future research and development of small-molecule inhibitors.
